BioDlink is dedicated to becoming the industry leading and trusted biopharmaceutical best partner for global clients.
With extensive practical experience, mature technical platforms and robust quality system, BioDlink has developed diversified strategic partnerships with domestic and international pharmaceutical companies to provide one-stop CDMO solutions for drug development and manufacturing, which help customers to accelerate the development and manufacturing of biologics, especially antibody-drug conjugates (ADCs), empowering to achieve high-quality development for the industry.
BioDlink (Stock Code: 1875.HK) was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited on 8 November 2019, which marks the Company's formally entrance into the international capital market.